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Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin
and resistant to three other anthracyclines
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Summary Drug resistance is a major obstacle to successful chemotherapy of primary liver cancer, which is
associated with high expression of the multidrug resistance (MDR) gene product P-glycoprotein (Pgp), a
multidrug efflux transporter. The most effective single agents in treatment of primary liver carcinoma belong to
the anthracycline family, yet several anthracyclines are known to be substrates for Pgp. In the present study, we
compared four anthracycines with respect to cell growth inhibition, intracellular accumulation and cellular
efflux using the HB8065/R human hepatoma cell line which is rich in Pgp, and the Pgp-poor parental line
HB8065/S. The anthracyclines were also administered in conjunction with the Pgp-modifying agents verapamil
and SDZ PSC 833 to assess modulation of resistance. The HB8065/R cells were sensitive to aclarubicin (ACL)
and highly resistant to epirubicin (EPI), doxorubicin (DOX) and daunorubicin (DNR). SDZ PSC 833
enhanced accumulation, decreased efflux and increased cytotoxicity of EPI, DOX and DNR in the HB8065/R
cells, but none of these effects was seen with ACL. In conclusion, ACL is apparently not transported by Pgp
and retains its activity in a multidrug-resistant human hepatoma cell line; such properties can be exploited for
clinical purposes.
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Cancer chemotherapy has major limitations because multi-
drug resistance (MDR) frequently prevents successful
treatment outcome in various human cancers. One impor-
tant mechanism of MDR is expulsion of certain anti-cancer
drugs (MDR drugs) from the interior of the malignant cells
by means of the multidrug efflux transporter P-glycoprotein
(Pgp), which enables the malignant cells to maintain tolerable
intracellular levels of these drugs (Juliano and Ling, 1976;
Endicott and Ling, 1989). Pgp expression has been shown to
correlate negatively with chemosensitivity and survival in
leukaemias (Campos et al., 1992; Marie et al., 1991),
lymphomas (Yuen and Sikic, 1994), childhood sarcomas
(Chan et al., 1990), neuroblastomas (Chan et al., 1991) and
ovarian carcinomas (Baekelandt et al., 1994).
Primary liver cancer is one of the most frequently fatal
human malignancies, and the response rate to chemotherapy
is less than 20% for a series of drug regimens (Falkson et al.,
1984). Overexpression of Pgp has been reported in 33-75%
of patients at diagnosis (Teeter et al., 1993; Itsubo et al.,
1994). Therefore, circumvention of Pgp-mediated MDR
might improve the prognosis of unresectable hepatocellular
carcinoma. Unfortunately, most of the clinically important
anthracyclines appear to be substrates for Pgp (reviewed by
Scambia et al., 1994). Among these are the type I
anthracyclines epirubicin (EPI), doxorubicin (DOX) and
daunorubicin (DNR), which preferentially inhibit the
synthesis of DNA. The type II anthracycline aclarubicin
(ACL), which consists of a 9-alkyl-aglycone (aklavinone) and
a trisaccharide (rhodosamine, 2-deoxyfucose and L-cinerulose
A), differs from EPI, DOX and DNR with respect to
mechanism of action, as ACL preferentially inhibits RNA
synthesis (Muggia and Green, 1991). The 9-alkyl substitution
of the anthracene A ring and certain sugar modifications
have also been associated with reduced affinity for Pgp and
retention of cytotoxic activity in certain MDR tumour cell
lines (Coley et al., 1990). Thus, ACL has some structural
characteristics in favour of MDR circumvention as opposed
to EPI, DOX and DNR (Figure 1).
ACL has a wide range of activity in tumours and human
xenografts (Hori et al., 1977; Oki et al., 1981), and shares the
toxic effects of the other anthracyclines, although it appears
to be less cardiotoxic (Dantchev et al., 1979; Mortensen,
1987). The cytotoxic activity of ACL is reported to be
retained in MDR variants of a mouse mammary tumour line
and a human small-cell lung cancer line (Coley et al., 1989,
1993). In clinical trials, several cases of complete remissions
have been reported with ACL in DNR-resistant acute
myeloid leukaemia (Machover et al., 1984; Pedersen-
Bjergaard et al., 1984). In unresectable hepatocellular
carcinoma, tumour-targeting chemotherapy with ACL has
been reported as highly effective, and patients with unknown
Pgp status have achieved response rates of 43-50% (Beppu
et al., 1991; Ichikara et al., 1989). The possible relationship
between a favourable response to ACL and circumvention of
Pgp-mediated MDR warrants study, which could be done in
vitro using a hepatoma cell line expressing high levels of Pgp.
In our laboratory, resistance to the second-generation
anthracycline epirubicin has been developed in a human
hepatoma cell line (HB8065) that has retained differentiated
liver cell functions (Knowles et al., 1980; Hall et al., 1991).
This resistant subline expresses high levels of Pgp compared
with the parental line (Lehne et al., 1994). In the present
study, the cytotoxicity and the cellular pharmacokinetics of
ACL, EPI, DOX and DNR were compared in the absence or
presence of the calcium channel blocker verapamil and the
novel cyclosporin D analogue SDZ PSC 833. Apparently,
certain calcium channel blockers and cyclosporins bind to
Pgp and counteract the active outward transport of MDR
drugs (Cornwell et al., 1987; Foxwell et al., 1989; Boesch et
al., 1991; Friche et al., 1992). The objective of the present
study was to investigate the selectivity of Pgp-mediated
resistance to different anthracyclines in human hepatoma cells
by assessments of cell growth inhibition, intracellular drug
accumulation, cellular drug efflux and response to resistance
modifiers.
Materials and methods
Chemicals
The cells were propagated in Eagle's modified minimum
essential medium (EMEM; Bio Whittaker, Walkersville, MA,
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Figure 1 The structural formulas of epirubicin, doxorubicin, daunorubicin and aclarubicin.
USA), supplemented with 10% fetal calf serum, L-glutamine
(0.05 m mmol ml-1), streptomycin (100 ug ml-'), penicillin
(100 u ml-'), and nystatin (40 u ml'- ). Trypsin-EDTA (Bio
Whittaker) was used to make single-cell suspensions from
monolayer cultures. The primary antibody MRK16, which
recognises a surface domain of Pgp (Hamada and Tsuruo,
1986), was a gift from Professor Takashi Tsuruo, Institute of
Molecular and Cellular Biosciences, The University of
Tokyo. The IgG2a isotypic control antibody mouse IgG2a
was purchased from Monosan, Uden, The Netherlands.
Verapamil hydrochloride was purchased from Knoll
(Ludwigshafen, Germany). SDZ PSC 833 was a gift from
Sandoz Pharma (Basle, Switzerland). Epirubicin (EPI) and
doxorubicin (DOX) were provided by Pharmacia (Milan,
Italy), daunorubicin (DNR) from Rh6ne Poulenc Rorer
(Birker0d, Denmark) and aclarubicin (ACL) from Medac
(Hamburg, Germany). A 500 Mug ml-' stock solution of each
anthracycline was prepared in sterile physiological saline
solution and kept frozen at -20°C for experimental use
within 6 months.
Scanningfluorimetry of anthracyclines
The emission and excitation spectra of native anthracycline
fluorescence were demonstrated by scanning fluorimetry,
using a Hitachi F-4500 fluorescence spectrophotometer
(Nissei Sangyo, Tokyo, Japan).
Cells and culture conditions
Human hepatoma cells HB8065 (American Type Culture
Collection), originating from biopsies of a primary hepato-
cellular carcinoma (Aden et al., 1979), were made resistant to
EPI by stepwise increase of the drug concentration in the
culture medium (Hall et al., 1991). The resistant cells
(HB8065/R) and the sensitive parental cells (HB8065/S)
were maintained and propagated as previously described
(Lehne et al., 1994).
Flow cytometry: immunofluorescence assay of Pgp expression
Specific immunofluorescence was obtained by a three-layer
staining technique. Cell suspensions were washed with
phosphate-buffered saline (PBS)/bovine serum albumin
(BSA) and incubated on ice for 60 min with MRK16
(25 pg ml-') or mouse IgG2a (25 jg ml-1) in PBS/BSA.
The second and third layer-staining protocols were carried
out with 100 pl of biotinylated horse anti-mouse IgG (1: 35
dilution in PBS/BSA) and 100 pl offluorescein isothiocyanate
(FITC)-c conjugated streptavidin (1: 35 dilution in PBS/BSA)
for 20-30 min each, with one PBS/BSA wash between them.
Immunofluorescence distributions were generated using a
FACScan flow cytometer (Becton Dickinson, San Jose, CA,
USA) with a 15 mW argon ion laser tuned to 488 nm. FITC
fluorescence of gated populations was collected through a
bandpass filter (FL1; bandwidth 515-545 nm). Calculations
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of logarithmically amplified fluorescence values were per-
formed in arithmetic mode using the LYSIS (Becton
Dickinson) computer program.
Cell growth inhibition assay
Approximately 50 x 103 cells were plated in 16 mm-diameter
wells (Costar, Cambridge, MA, USA) and grown in 1 ml of
drug-free medium (EMEM) for the first 24 h. The wells were
then supplemented with the appropriate anthracycline at
certain dose levels either alone or together with SDZ PSC 833
(1.5 Mg ml-'). Six replicate cultures were made from each of
three dose levels and from untreated controls from both cell
lines (HB8065/R and HB8065/S). After 72 h the cells were
harvested by trypsinisation and counted in a Coulter Counter
ZM (Coulter Electronics, Luton, UK). The dose level
required for 50% inhibition of cell growth (GI50) was
calculated from linear plots of dose vs cell number. The
resistance factor (RF) was defined as the ratio between the
GI50 values obtained in HB8065/R and HB8065/S cells.
Modulation of growth inhibition was assessed by co-
incubation with SDZ PSC 833. The modulating factor
(MF) was defined as the ratio between the GI50 values of
non-modified and modified HB8065/R cells.
Flow cytometry. intracellular accumulation of anthracyclines
The cells were grown in drug-free medium for 24 h before
flow cytometric analysis. FACScan (Becton Dickinson) and
Ortho Cytofluorograf 50-H (Ortho Diagnostic Systems, MA,
USA) laser flow cytometers, both tuned to 488 nm laser
excitation wavelength and running at 15 mW and 250 mW
respectively, were used to generate anthracycline fluorescence.
In the FACScan, fluorescence was transmitted thorugh a
bandpass filter of 564-606 nm (FL2) and logarithmically
amplified. In the Cytofluorograf, fluorescence emitted above
510 nm was collected on log scale and transformed to linear
values (Lehne et al., 1995). Correlated forward angle (a
relative measure of cell size) and right angle (a measure of
cell granularity) light scatter measurements were generated to
exclude dead cells and debris from analyses. Acquired data
from 5000-10 000 events were analysed using LYSIS
(Becton Dickinson) and MULTI2D (Phoenix Flow Systems,
San Diego, CA, USA) computer programs. Changes in the
fluorescence intensity of EPI, DOX, DNR and ACL were
recorded by repeated measurements during incubation with
1 - 10 Mg ml- ' of the drugs at 37°C for up to 180 min. Co-
incubation with verapamil (5 Mug ml-') and PSC 833
(1.5 Mg ml-') was carried out to study any potential
modification of anthracycline membrane transport.
Cellular efflux of anthracyclines
Approximately 200 x 103 cells were plated in 16 mm-diameter
wells (Costar) and grown in 1 ml of medium (EMEM) for
6-7 days. The selection pressure of EPI (125 ng ml-') was
maintained in the HB8065/R culture until 24 before the
experiment, at which point they were grown in drug-free
medium. The cells were then incubated in media containing
5 Mg ml- 1 of either EPI, DOX, DNR or ACL for 90 min at
4°C. The temperature was kept low in order to load the cells
with the drug at conditions which minimise active drug
transport by Pgp. Afterwards, the cells were washed once
and incubated at 37°C for 120 min in Hanks' balanced salt
solution IX (HBSS) without phenol red (Bio Whittaker,
Walkersville, MA, USA). After incubation, samples of
HBSS were withdrawn from each well and placed in a
Hitachi F-4500 fluorescence spectrophotometer (Nissei
Sangyo, Tokyo, Japan). In series of 4-6 parallels, the
drug fluorescence from each anthracycline was measured
using 488 nm excitation and 594 nm emission wavelengths.
Half of the cell samples were co-incubated with SDZ PSC
833 (1.5 Mg ml-') at 37°C to assess possible modification of
drug efflux.
Confocal laser scanning microscopy
Suspensions ofHB8065/R and HB8065/S cells were incubated
with anthracyclines (5 10 Mg ml-') for 60 min at 37°C.
Viable cell suspensions were examined in a Nikon Labophot
microscope (Nikon, Tokyo, Japan) with an epifluorescence
attachment and equipped with a Bio-Rad MRC 600 confocal
laser scan unit with a krypton/argon laser using the 488 nm
line, a KI double dichroic excitation filter block and a K2
dichroic emission filter block (Biorad Microscience, Hertford-
shire, UK). A Polaroid freeze frame unit (Polaroid, Cam-
bridge, MA, USA) was attached for photographic
documentation of acquired images. The confocal microscopic
images were taken at x 72 objective magnification.
Results
Scanningfluorimetry
The native fluorescence of the anthracyclines allowed
photodetection of these drugs when excited with light of
certain wavelengths. Using scanning fluorimetry, the excita-
tion and emission maxima were 490 nm and 590 nm for EPI
and DOX respectively, 490 nm and 594 nm for DNR, and
440 nm and 520 nm for ACL. The argon ion lasers in the
flow cytometers and in the confocal laser scanning
microscope delivered coherent excitation light of 488 nm
wavelength, which yielded almost 100% of maximal
fluorescence for EPI, DOX and DNR and approximately
50-75% of maximal fluorescence for ACL at the emission
wavelengths collected.
Pgp expression
The distributions of Pgp expression in HB8065/R and
HB8065/S cells were determined by flow cytometric immuno-
fluorescence detection using the anti-Pgp monoclonal anti-
body MRK16. A low expression of Pgp was seen in the
HB8096/S cells compared with the 12-fold higher expression
in the HB8065/R cells in terms of Pgp-specific immunofluor-
escence (Figure 2).
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Figure 2 Histograms showing the distribution of anti-Pgp
immunofluorescence of resistant (R) and sensitive (S) human
hepatoma cells using MRK 16. Open distributions represent the
irrelevant isotypic control antibody. The fluorescence statistics
presented in the upper left corner display geometric mean (Gm)
and coefficient of variation (CV) for the positive populations.Aclarubicin circumvents Pgp-mediated drug resistance
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Cell growth inhibition
The HB8065/S and HB8065/R cell lines also differed with
respect to susceptibility to anthracyclines, using growth
inhibition as a measure of cytotoxicity. After continuous
treatment of HB8065/R cells with EPI, DOX, DNR and
ACL for 3 days, the G150 values were 2118 ng ml-',
1784 ng ml-', 362 ng ml-' and 38 ng ml-' respectively. The
corresponding G150 values for HB8065/S cells were
46 ng ml-', 39 ng ml-', 40 ng ml-' and 29 ng ml-', which
resulted in RF values of 46, 46, 9 and 1 respectively (Figure
3). Hence, the HB8065/R cells were sensitive to ACL but
resistant to EPI, DOX and DNR.
To test if the variation in anthracycline resistance was
correlated with Pgp activity, growth inhibition studies were
carried out in the presence of SDZ PSC 833, which is a potent
modifier of Pgp-mediated MDR (Boesch et al., 1991). After
treatment with SDZ PSC 833, the GIs ofHB8065/R increased
by a factor of 46 (modifying factor, MF) for EPI (G1_0
untreated, 1878 ng ml-'; G150 treated, 41 ng ml-'), 45 for
DOX (Glso untreated, 1967 ng ml-'; GIso treated, 44 ng ml-')
and 11 for DNR (GI50 untreated, 375 ng ml-'; GI50 treated,
34 ng ml-') (Figure 4a-c). There was practically no change in
G150 for ACL (GI,0 untreated, 43 ng ml-', G150 treated,
36 ng ml-') (Figure 4d). Thus, the resistance to EPI, DOX
and DNR was eliminated by SDZ PSC 833, while there was no
change in the cytotoxicity of ACL. Even when the treatment
duration was reduced from 3 days to 3 h, the sensitivity of
HB8065/R cells to ACL persisted, the RF values being 1 for
ACL (GI50 HB8065/S, 356 ng ml-'; G150 HB8065/R,
467 ng ml-'), 20 for EPI (GI50 HB8065/S, 250 ng ml-'; G150
HB8065/R, 5000 ng ml-1), 17 for DOX (GI50 HB8065/S,
286 ng ml-'; G150 HB8065/R, 4900 ng ml-') and 23 for DNR
(Gl50 HB8065/S, 184 ng ml-', G150 HB8065/R, 4295 ng ml-').
SDZ PSC had absolutely no effect on the cytotoxicity of EPI
or ACL in the sensitive HB8065/S cells and the growth curves
of modified and non-modified cells were practically identical
(data not shown).
Laser confocal microscopy
The distribution of anthracycline fluorescence in HB8065/R
and HB8065/S cells was demonstrated by laser scanning
microscopy, performed after 60 min of incubation with the
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Figure 3 The growth inhibition curves for 72h continuous treatment with EPI (a), DOX (b), DNR (c) and ACL (d) show the
correlations between the anthracycline dose levels and the relative cell numbers of HB8065/S cells (El) and HB8065/R cells (A). The
error bars show the 95% confidence intervals. The calculated resistance factors (RF) are given in the upper right corner of each
diagram.
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Figure 4 The growth inhibition curves for 72h continuous treatment with EPI (a), DOX (b), DNR (c) and ACL (d) alone (A) or
in combination with SDZ PSC 833 (El) show the correlation between the anthracycline dose levels and the relative number of
HB8065/R cell lines in culture. The error bars show the 95% confidence intervals. The calculated modulation factors (MF) are given
in the upper right corner of each diagram.
appropriate drug. Cells incubated with EPI or DOX
(10 jug ml-') demonstrated weakly detectable fluorescence in
the nuclear membrane and the chromoplasm of HB8065/R
cells, whereas a strikingly brighter fluorescence with similar
distribution was seen in the majority of HB8065/S cells.
Fluorescent vesicles were seen in the cytoplasm of both cell
types (micrographs not shown). Cells incubated with DNR
(5 ,ug ml-') showed predominantly cytoplasmic fluorescence,
both diffuse and vesicular, and the fluorescence was clearly
brighter in the HB8065/S cells (Figure 5a) than in the
HB8065/R cells (Figure 5b). On the other hand, indiscrimi-
nately bright cytoplasmic fluorescence of ACL (5 Mg ml-'),
with a mixed diffuse and vesicular distribution, was seen in
both cell types (Figure Sc and d). There was no detectable
nuclear fluorescence of ACL.
Cellular accumulation of anthracyclines
The intracellular drug fluorescence was quantified by flow
cytometry after 60 min of incubation and correlated by linear
regression with the drug amount added to the medium. The
drug fluorescence increased linearly with increasing concen-
tration of all anthracyclines in the medium (range 0.999-
1.000) within a dose range of 1-10 jug ml-' in both HB8065/
R and HB8065/S cells (Figure 6a-d). Assuming that the
slope of the regression line represents a measure of
intracellular drug retention, the HB8065/S cells accumulate
2.6 times more EPI, 2.3 times more DNR and 1.6 times more
DOX than HB8065/R cells. In contrast, incubation with ACL
for 1 h led to 1.7 times higher intracellular levels in the
HB8065/R cells, despite the relatively high expression of Pgp
in these cells compared with the parental HB8065/S cells. The
total fluorescence from each anthracycline differed in
intensity, and at a drug concentration of 5 ,ug ml-' the
fluorescence intensity of DNR was 4.3-fold that of ACL, 3.6-
fold that of DOX and 3.5-fold that of EPI in HB8065/R cells.
Individual profiles of drug fluorescence in resistant (R)
and sensitive (S) hepatoma cells during 3 h incubation with
each anthracycline are presented in Figure 7. Flow
cytometric measurements revealed a rapid influx of all four
anthracyclines in both HB8065/R and HB8065/S cells. The
rate of anthracycline accumulation appeared to be similar
for the two cell types in the first few minutes of incubation.
After 15-30 min, the accumulation rate in the HB8065/R
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cells subsided, as the fluorescence of the anthracyclines
reached a plateau at this stage. In HB8065/S cells, the
fluorescence of EPI and DOX continued to increase for 45
and 150 min, respectively, whereas the increase in fluores-
a
b
cence of DNR and ACL had already subsided within
15 min of incubation. Thereafter, only a slight increase in
drug accumulation continued throughout the incubation
period. After 3 h, the sensitive cells had accumulated EPI,
d
Figure 5 Confocal microscopic images showing the fluorescence distribution of DNR in HB8065/S cells (a) and in HB8065/R cells
(b) and the fluorescence distribution of ACL in HB6085/S cells (c) and in HB8065/R cells (d) after 60min incubation with 5 ,ugml- l
of each drug. Bar= 25,um.Aclarubicin circumvents Pgp-mediated drug resistance
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Figure 6 Dose-fluorescence relationship after 60min incubation of sensitive (S) and resistant (R) human hepatoma cells with EPI
(a), DOX (b), DNR (c), and ACL (d).
DOX and DNR at intracellular levels of 1.9, 1.7 and 2.1
times those in the resistant cells. On the other hand, the
resistant cells accumulated 1.4 times more ACL than the
sensitive cells.
Modification of membrane transport
The resistant HB8065/R cells were incubated for 90 min with
5 Mg ml-' ofeach anthracycline alone or in combination with
verapamil (5 ,ug ml-') or SDZ PSC 833 (1.5 jg ml- ). The
two modifying agents were added to the cells after 30 min
and pronounced changes in drug fluorescence appeared
immediately (Figure 8). The addition of VPL and SDZ
PSC 833 resulted in 2- to 3-fold enhancement of the cellular
fluorescence of DNR, DOX and EPI. In contrast, essentially
no change was seen in the fluorescence of ACL after
treatment with either VPL or SDZ PSC 833.
If the changes in intracellular drug fluorescence were
induced by interaction between the modifying agent and
Pgp, a corresponding change in drug efflux should occur
as well. The results of the drug efflux studies are
summarised in Table I. We measured significant reduc-
tions of effluxed EPI, DOX and DNR from HB8065/R
cells after treatment with SDZ PSC 833 (1.5 Mg ml-'), but
no change was seen in the efflux of ACL. On the other
hand, identical treatment of the sensitive HB8065/S cells
was not accompanied by significant changes in the efflux
of any of the anthracyclines.
Discussion
Several mechanisms of MDR have been described in murine
and human cancer cell lines. Apparently, the most common
form of MDR is Pgp-mediated increased drug efflux resulting
in decreased intracellular drug concentrations. Pgp has a
broad specificity to multiple hydrophobic xenobiotics
(reviewed by Licht et al., 1994), and many anthracyclines
have been shown to be substrates of Pgp (Mulder et al.,
1995). In tumour cell lines, non-Pgp-mediated resistance to
anthracyclines has been linked to reduced activity of
topoisomerase II (Cole et al., 1991; Eijdems et al., 1995),
increased activity of glutathione S-transferase (Batist et al.,
1986) and reduced activity of cytochrome P450 reductase
(Mimnaugh et al., 1989). Recently, a new multidrug efflux
transporter, multidrug resistance protein (MRP), has been
identified (Cole et al., 1992), and overexpression of Pgp and
MRP may coexist (Brock et al., 1995).
Our results show that the HB8065/R cells remain sensitive
to ACL despite a pronounced overexpression of Pgp, and
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Figure 7 Changes in fluorescence levels in resistant (V) and sensitive (v) human hepatoma cells during 180min of incubation with
EPI 10jpgml- 1 (a), DOX 10 igml-l (b), DNR 1 Mgml- 1 (c) or ACL 1 ,gml- 1 (d) (Cytofluorograf analysis).
that ACL accumulates unabated in these cells. The Pgp-
modifying agents used in this study did not influence the
cytotoxicity, accumulation or efflux of ACL. On the other
hand, treatment of HB8065/R cells with SDZ PSC 833
increased the accumulation and decreased the efflux of EPI,
DOX and DNR, resulting in multiplied sensitivity, which
became equal to that of the parental HB8065/S cells. Thus,
Pgp seemed to be the key determinant to explain the
difference in cytotoxicity and cellular pharmacokinetics seen
in the four anthracyclines. Our findings strongly indicate that
ACL is a poor substrate for active outward transport by Pgp,
which is in agreement with previous reports of MDR
circumvention with 9-alkyl or morpholinyl substituted
anthracyclines in cell lines (Scott et al., 1986; Streeter et al.,
1986; Coley et al., 1990). Two recent reports suggest that
ACL may also circumvent drug resistance due to altered
expression of topoisomerase II and glutathione S-transferase
(Jensen et al., 1993; Okuyama et al., 1994).
The assessment of cytotoxicity was performed using
growth inhibition assays that measure cell growth by
electronic cell counting. Previous attempts to perform
colony-forming assays in HB8065/R and HB8065/S cells
have been unsuccessful because both lines failed to clone
reproducibly on soft agar (Hall et al., 1991). Although
electronic assessment of growth inhibition does not
discriminate between cells of poor or of good proliferating
capacity, the results from growth inhibition assays of
anthracycline toxicity have been shown to correlate with
those of clonogenic assays in certain pairs of parental and
MDR cell lines (Bhalla et al., 1985; Hall et al., 1991).
Following a 3 h treatment course the growth inhibition assay
revealed a 20-fold resistance to EPI, DOX and DNR in the
resistant human hepatoma cell line relative to the parental
line, which corresponded with approximately 2-fold lower
intracellular drug accumulation in the resistant cells than in
the parental cells. By extending the treatment duration to 3
days, the resistance to EPI and DOX was doubled and the
resistance to DNR was halved. Thus, the dose - response
relationship was schedule dependent. Correspondingly, it has
previously been demonstrated that cell killing by doxorubicin
is an exponential function of drug exposure time in Chinese
hamster ovary cells (Bates et al., 1985), and that lengthening
the drug exposure time reduces the relative resistance to
vincristine in two human colon carcinoma cell lines (Bates et
al., 1994).
Using flow cytometry, we demonstrated rapid accumula-
tion of all the anthracyclines in both cell types within minutes
of incubation, which is in agreement with previous in vitro
and in vivo findings of rapid influxes of anthracyclines across
cellular membranes (Meriwether & Bachur, 1972; Egorin et
al., 1974; Bachur, 1976). In both hepatoma cell lines, the
fluorescence of DNR and ACL reached a plateau within
15 min. It was previously shown that ACL accumulates more
rapidly than DNR or DOX in L1210 ascitic cells (Zenebergh
et al., 1982), and that the rate of cellular uptake increases by
increasing lipophilicity of the anthracyclines (Skovsgaard,
1987; Wheeler and Kessel, 1980). EPI and DOX reached a
plateau within 15 min in the resistant cells but continued to
accumulate for 45-150 min in the parental cells. Thus, the
drug accumulation was not only governed by physicochem-
ical characteristics of the drugs, but also by cellular
characteristics.
The confocal laser microscopic images confirmed the flow
cytometric findings by showing less fluorescent brightness of
EPI, DOX and DNR in the resistant cells than in the
sensitive ones, and by showing no difference in fluorescent
brightness of ACL in the two cell types. It has been
demonstrated by others that the fluorescence intensity of
intracellular DNR parallels measurements of uptake of the
corresponding radioactive drug (Bhalla et al., 1985).
However, the intracellular anthracycline fluorescence does
not accurately reflect the drug content because binding to
DNA may cause quenching of the fluorescence, which is
particularly pronounced for ACL (Skovsgaard, 1987;
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Figure 8 Changes in the intracellular drug fluorescence HB8065/R cells during 180min of incubation with EPI (a), DOX (b), DNR
(c) and ACL (d). The solid line represents cells treated with anthracycline alone (El), and the dashed line represents anthracycline-
treated cells modified with either SDZ PSC 833 (@) or verapamil (-). The time points for addition of anthracyclines and modifiers
are indicated by open and closed arrows respectively, (FACScan analysis).
Table I Modification of drug efflux by SDZ PSC 833 in HB8065/R
and HB8065/S cells. The modified drug efflux was compared with the
natural efflux by means of independent samples t-test
Drug efflux Drug efflux
(ng mrl') (ng ml-)
(No modifier) SDZ PSC 833 P
HB8065/R
EPI 350+2 235+ 18 0.001
DOX 154+11 80+3 0.003
DNR 712+36 515+37 0.009
ACL 2554+80 2472+87 NS
HB8065/S
EPI 183+12 173+8 NS
DOX 66+4 46+11 NS
DNR 719+35 682+20 NS
ACL 1065+72 1023+62 NS
NS, not significant.
Tarasiuk et al., 1989). The fluorescence intensity of free ACL
has been measured to be 200 times that of nucleus-bound
drug (Millot et al., 1989). In the cytoplasm of the HB8065/S
cells, and to a much lesser extent in the resistant HB8065/R
cells, the anthracycline fluorescence appeared in numerous
cytoplasmic vesicles. Similar vesicles have been demonstrated
in both MDR cell lines and corresponding parental lines
(Weaver et al., 1991), and may represent drug accumulation
in lysosomes. It is possible that higher drug concentrations
may activate non-specific adsorptive endocytosis, which has
been demonstrated in anthracycline-resistant Ehrlich ascites
tumour cell lines (Sehested et al., 1987).
Our results showed that low accumulation of EPI and
DOX paralleled high efflux of these cytotoxics in the pair of
cell lines studied. Because SDZ PSC 833 significantly reduced
the efflux of EPI, DOX and DNR from the resistant human
hepatoma cells but not from the sensitive ones, it is likely
that Pgp was mainly responsible for the variations in the
efflux of these anthracyclines. The efflux of ACL was not
altered by SDZ PSC 833 in any of the cell types, and the
greater efflux of ACL from the resistant human hepatoma
cells was obviously unrelated to Pgp, but correlated with an
increased accumulation of ACL in the resistant cells.
Interestingly, it has been reported that there is no difference
in the efflux of ACL between parental and resistant lines of
human small-cell lung cancer and mouse mammary tumour
(Coley et al., 1993). Thus, there may exist alternative
transport mechanisms for ACL in certain cell types that
may also express high levels of Pgp.
The applied anthracycline doses in this study were in the
upper range or slightly above achievable plasma concentra-
tions in patients after standard bolus i.v. injections (Martini
et al., 1984; Paul et al., 1989). An- i.v. bolus injection of 60-
120 mg m-2 ACL yields initially 2-3 nmol 1' (Egorin et al.,
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1982), which is approximately half ofthe highest applied dose
of ACL in this study. The verapamil dose that restored the
net drug accumulation in HB8065/R cells to the level of
HB8065/S cells or above was approximately 10 times a
clinically relevant plasma concentration in cardiac patients
(Frishman et al., 1982). On the other hand, it has been shown
in rats that verapamil concentrates 40-fold in liver tissue
compared with plasma (Hamann et al., 1983). The SDZ PSC
833 dose that we applied in the culture media was similar to
tolerable plasma concentrations obtained with the drug in
clinical trials (Sonneveld et al., 1994) and thus this drug
seems more clinically promising.
In the present study, a comparison of four different
anthracyclines with respect to cytotoxicity, intracellular
accumulation, cellular efflux and response to Pgp-modifying
agents strongly indicates Pgp as the major resistance
mechanism responsible for the difference that has been
demonstrated between ACL and the type I anthracyclines
EPI, DOX and DNR. Therefore, we may conclude that the
9-alkyl trisaccharide ACL appears to be a poor substrate of
Pgp in cultured human hepatoma cells. Translation of this
unique feature of ACL into clinical practice would mean that
treatment of unresectable hepatocellular carcinoma may
benefit from tailoring the chemotherapeutic regimens
according to the Pgp status of the tumour.
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